APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neoantigen Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Neoantigen Vaccine Industry Growth and Trends Forecast to 2032

31 December 2025122 pages

Choose your research edition.

Industry ResearchNeoantigen Vaccine Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Neoantigen Vaccine Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Neoantigen Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neoantigen Vaccine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Neoantigen Vaccine Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

According to APO Research, the global Neoantigen Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Neoantigen Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Neoantigen Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neoantigen Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Neoantigen Vaccine market include Merck & Co Inc, Eli Lilly and Company, Pfizer, ZIOPHARM Oncology, Vaximm AG, Vaccibody AS, Roche Holding AG, OSE Immunotherapeutics and Novogene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Neoantigen Vaccine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Neoantigen Vaccine market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neoantigen Vaccine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neoantigen Vaccine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Neoantigen Vaccine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Neoantigen Vaccine Market by Company

Merck & Co Inc

Eli Lilly and Company

Pfizer

ZIOPHARM Oncology

Vaximm AG

Vaccibody AS

Roche Holding AG

OSE Immunotherapeutics

Novogene

Nouscom

Moderna

Medigene AG

ISA Pharmaceuticals

Gritstone Bio

Genocea Biosciences Inc

BrightPath Biotherapeutics

BioNTech

Avidea Technologies

Agenus Inc

Advaxis

Neoantigen Vaccine Segment by Type

Personalized Vaccine

Off-the shelf Vaccine

Neoantigen Vaccine Segment by Application

Gastrointestinal Cancer

Lung Cancer

Melanoma Cancer

Brain Cancer

Others

Neoantigen Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neoantigen Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neoantigen Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neoantigen Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Neoantigen Vaccine companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Neoantigen Vaccine Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Neoantigen Vaccine Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Neoantigen Vaccine Market Share by Region (2021-2026) Table 4. Global Neoantigen Vaccine Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Neoantigen Vaccine Market Share by Region (2027-2032) Table 6. Global Neoantigen Vaccine Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Neoantigen Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Neoantigen Vaccine Market Size Share by Type (2021-2026) Table 9. Global Neoantigen Vaccine Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Neoantigen Vaccine Market Size Share Forecasted by Type (2027-2032) Table 11. North America Neoantigen Vaccine Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Neoantigen Vaccine Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Neoantigen Vaccine Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Neoantigen Vaccine Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Neoantigen Vaccine Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Neoantigen Vaccine Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Neoantigen Vaccine Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Neoantigen Vaccine Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Neoantigen Vaccine Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Neoantigen Vaccine Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Neoantigen Vaccine Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Neoantigen Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Neoantigen Vaccine Market Size Share by Application (2021-2026) Table 24. Global Neoantigen Vaccine Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Neoantigen Vaccine Market Size Share Forecasted by Application (2027-2032) Table 26. North America Neoantigen Vaccine Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Neoantigen Vaccine Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Neoantigen Vaccine Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Neoantigen Vaccine Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Neoantigen Vaccine Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Neoantigen Vaccine Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Neoantigen Vaccine Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Neoantigen Vaccine Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Neoantigen Vaccine Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Neoantigen Vaccine Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Neoantigen Vaccine Industry Trends Table 37. Neoantigen Vaccine Industry Drivers Table 38. Neoantigen Vaccine Industry Opportunities and Challenges Table 39. Neoantigen Vaccine Industry Restraints Table 40. Global Neoantigen Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Neoantigen Vaccine Revenue Market Share by Company (2021-2026) Table 42. Global Neoantigen Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Neoantigen Vaccine Key Company Headquarters & Area Served Table 44. Global Neoantigen Vaccine Company, Product Type & Application Table 45. Global Neoantigen Vaccine Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Neoantigen Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Merck & Co Inc Company Information Table 49. Merck & Co Inc Business Overview Table 50. Merck & Co Inc Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Merck & Co Inc Neoantigen Vaccine Product Portfolio Table 52. Merck & Co Inc Recent Development Table 53. Eli Lilly and Company Company Information Table 54. Eli Lilly and Company Business Overview Table 55. Eli Lilly and Company Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Eli Lilly and Company Neoantigen Vaccine Product Portfolio Table 57. Eli Lilly and Company Recent Development Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Pfizer Neoantigen Vaccine Product Portfolio Table 62. Pfizer Recent Development Table 63. ZIOPHARM Oncology Company Information Table 64. ZIOPHARM Oncology Business Overview Table 65. ZIOPHARM Oncology Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. ZIOPHARM Oncology Neoantigen Vaccine Product Portfolio Table 67. ZIOPHARM Oncology Recent Development Table 68. Vaximm AG Company Information Table 69. Vaximm AG Business Overview Table 70. Vaximm AG Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Vaximm AG Neoantigen Vaccine Product Portfolio Table 72. Vaximm AG Recent Development Table 73. Vaccibody AS Company Information Table 74. Vaccibody AS Business Overview Table 75. Vaccibody AS Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Vaccibody AS Neoantigen Vaccine Product Portfolio Table 77. Vaccibody AS Recent Development Table 78. Roche Holding AG Company Information Table 79. Roche Holding AG Business Overview Table 80. Roche Holding AG Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Roche Holding AG Neoantigen Vaccine Product Portfolio Table 82. Roche Holding AG Recent Development Table 83. OSE Immunotherapeutics Company Information Table 84. OSE Immunotherapeutics Business Overview Table 85. OSE Immunotherapeutics Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. OSE Immunotherapeutics Neoantigen Vaccine Product Portfolio Table 87. OSE Immunotherapeutics Recent Development Table 88. Novogene Company Information Table 89. Novogene Business Overview Table 90. Novogene Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Novogene Neoantigen Vaccine Product Portfolio Table 92. Novogene Recent Development Table 93. Nouscom Company Information Table 94. Nouscom Business Overview Table 95. Nouscom Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Nouscom Neoantigen Vaccine Product Portfolio Table 97. Nouscom Recent Development Table 98. Moderna Company Information Table 99. Moderna Business Overview Table 100. Moderna Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Moderna Neoantigen Vaccine Product Portfolio Table 102. Moderna Recent Development Table 103. Medigene AG Company Information Table 104. Medigene AG Business Overview Table 105. Medigene AG Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Medigene AG Neoantigen Vaccine Product Portfolio Table 107. Medigene AG Recent Development Table 108. ISA Pharmaceuticals Company Information Table 109. ISA Pharmaceuticals Business Overview Table 110. ISA Pharmaceuticals Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. ISA Pharmaceuticals Neoantigen Vaccine Product Portfolio Table 112. ISA Pharmaceuticals Recent Development Table 113. Gritstone Bio Company Information Table 114. Gritstone Bio Business Overview Table 115. Gritstone Bio Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Gritstone Bio Neoantigen Vaccine Product Portfolio Table 117. Gritstone Bio Recent Development Table 118. Genocea Biosciences Inc Company Information Table 119. Genocea Biosciences Inc Business Overview Table 120. Genocea Biosciences Inc Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Genocea Biosciences Inc Neoantigen Vaccine Product Portfolio Table 122. Genocea Biosciences Inc Recent Development Table 123. BrightPath Biotherapeutics Company Information Table 124. BrightPath Biotherapeutics Business Overview Table 125. BrightPath Biotherapeutics Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. BrightPath Biotherapeutics Neoantigen Vaccine Product Portfolio Table 127. BrightPath Biotherapeutics Recent Development Table 128. BioNTech Company Information Table 129. BioNTech Business Overview Table 130. BioNTech Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. BioNTech Neoantigen Vaccine Product Portfolio Table 132. BioNTech Recent Development Table 133. Avidea Technologies Company Information Table 134. Avidea Technologies Business Overview Table 135. Avidea Technologies Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Avidea Technologies Neoantigen Vaccine Product Portfolio Table 137. Avidea Technologies Recent Development Table 138. Agenus Inc Company Information Table 139. Agenus Inc Business Overview Table 140. Agenus Inc Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Agenus Inc Neoantigen Vaccine Product Portfolio Table 142. Agenus Inc Recent Development Table 143. Advaxis Company Information Table 144. Advaxis Business Overview Table 145. Advaxis Neoantigen Vaccine Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. Advaxis Neoantigen Vaccine Product Portfolio Table 147. Advaxis Recent Development Table 148. North America Neoantigen Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. North America Neoantigen Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 150. North America Neoantigen Vaccine Market Share by Country (2021-2026) Table 151. North America Neoantigen Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. North America Neoantigen Vaccine Market Share Forecast by Country (2027-2032) Table 153. Europe Neoantigen Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Europe Neoantigen Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 155. Europe Neoantigen Vaccine Market Share by Country (2021-2026) Table 156. Europe Neoantigen Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Europe Neoantigen Vaccine Market Share Forecast by Country (2027-2032) Table 158. Asia-Pacific Neoantigen Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Asia-Pacific Neoantigen Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 160. Asia-Pacific Neoantigen Vaccine Market Share by Country (2021-2026) Table 161. Asia-Pacific Neoantigen Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Asia-Pacific Neoantigen Vaccine Market Share Forecast by Country (2027-2032) Table 163. Latin America Neoantigen Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Latin America Neoantigen Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 165. Latin America Neoantigen Vaccine Market Share by Country (2021-2026) Table 166. Latin America Neoantigen Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Latin America Neoantigen Vaccine Market Share Forecast by Country (2027-2032) Table 168. Middle East & Africa Neoantigen Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Middle East & Africa Neoantigen Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 170. Middle East & Africa Neoantigen Vaccine Market Share by Country (2021-2026) Table 171. Middle East & Africa Neoantigen Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Middle East & Africa Neoantigen Vaccine Market Share Forecast by Country (2027-2032) Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Neoantigen Vaccine Product Image Figure 3. Global Neoantigen Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Neoantigen Vaccine Market Size (2021-2032) & (US$ Million) Figure 5. Global Neoantigen Vaccine Market Share by Region: 2025 VS 2032 Figure 6. Global Neoantigen Vaccine Market Share by Region (2021-2032) Figure 7. North America Neoantigen Vaccine Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Neoantigen Vaccine Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Neoantigen Vaccine Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Neoantigen Vaccine Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Neoantigen Vaccine Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Personalized Vaccine Image Figure 13. Global Personalized Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Off-the shelf Vaccine Image Figure 15. Global Off-the shelf Vaccine Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Neoantigen Vaccine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Neoantigen Vaccine Market Share by Type 2025 VS 2032 Figure 18. North America Neoantigen Vaccine Market Size Share by Type (2021-2032) Figure 19. Europe Neoantigen Vaccine Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Neoantigen Vaccine Market Size Share by Type (2021-2032) Figure 21. Latin America Neoantigen Vaccine Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Neoantigen Vaccine Market Size Share by Type (2021-2032) Figure 23. Gastrointestinal Cancer Image Figure 24. Global Gastrointestinal Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Lung Cancer Image Figure 26. Global Lung Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Melanoma Cancer Image Figure 28. Global Melanoma Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Brain Cancer Image Figure 30. Global Brain Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Others Image Figure 32. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Global Neoantigen Vaccine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Neoantigen Vaccine Market Share by Application 2025 VS 2032 Figure 35. North America Neoantigen Vaccine Market Size Share by Application (2021-2032) Figure 36. Europe Neoantigen Vaccine Market Size Share by Application (2021-2032) Figure 37. Asia-Pacific Neoantigen Vaccine Market Size Share by Application (2021-2032) Figure 38. Latin America Neoantigen Vaccine Market Size Share by Application (2021-2032) Figure 39. Middle East and Africa Neoantigen Vaccine Market Size Share by Application (2021-2032) Figure 40. Global Top 5 and 10 Neoantigen Vaccine Players Market Share by Revenue in 2025 Figure 41. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 42. North America Neoantigen Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. North America Neoantigen Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. North America Neoantigen Vaccine Market Share by Country (2021-2032) Figure 45. Europe Neoantigen Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Neoantigen Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Neoantigen Vaccine Market Share by Country (2021-2032) Figure 48. Asia-Pacific Neoantigen Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Asia-Pacific Neoantigen Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Asia-Pacific Neoantigen Vaccine Market Share by Country (2021-2032) Figure 51. Latin America Neoantigen Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Latin America Neoantigen Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Neoantigen Vaccine Market Share by Country (2021-2032) Figure 54. Middle East & Africa Neoantigen Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Middle East & Africa Neoantigen Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Middle East & Africa Neoantigen Vaccine Market Share by Country (2021-2032) Figure 57. Years Considered Figure 58. Research Process Figure 59. Key Executives Interviewed

Scope & coverage.

Types
  • Personalized Vaccine
  • Off-the shelf Vaccine
Applications
  • Gastrointestinal Cancer
  • Lung Cancer
  • Melanoma Cancer
  • Brain Cancer
  • Others
Companies covered
  • Merck & Co Inc
  • Eli Lilly and Company
  • Pfizer
  • ZIOPHARM Oncology
  • Vaximm AG
  • Vaccibody AS
  • Roche Holding AG
  • OSE Immunotherapeutics
  • Novogene
  • Nouscom
  • Moderna
  • Medigene AG
  • ISA Pharmaceuticals
  • Gritstone Bio
  • Genocea Biosciences Inc
  • BrightPath Biotherapeutics
  • BioNTech
  • Avidea Technologies
  • Agenus Inc
  • Advaxis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Neoantigen Vaccine Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Neoantigen Vaccine Market Size by Region (2021-2032)
  5. 1.4.1 Global Neoantigen Vaccine Market Size by Region (2021-2026)
  6. 1.4.2 Global Neoantigen Vaccine Market Size by Region (2027-2032)
  7. 1.5 Key Regions Neoantigen Vaccine Market Size (2021-2032)
  8. 1.5.1 North America Neoantigen Vaccine Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Neoantigen Vaccine Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Neoantigen Vaccine Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Neoantigen Vaccine Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Neoantigen Vaccine Market Size Growth Rate (2021-2032)
2 Neoantigen Vaccine Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Personalized Vaccine
  3. 2.1.2 Off-the shelf Vaccine
  4. 2.2 Global Neoantigen Vaccine Market Size by Type
  5. 2.2.1 Global Neoantigen Vaccine Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Neoantigen Vaccine Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Neoantigen Vaccine Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Neoantigen Vaccine Market Size by Regions
  9. 2.3.1 North America Neoantigen Vaccine Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Neoantigen Vaccine Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Neoantigen Vaccine Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Neoantigen Vaccine Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Neoantigen Vaccine Market Size Breakdown by Type (2021-2026)
3 Neoantigen Vaccine Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Gastrointestinal Cancer
  3. 3.1.2 Lung Cancer
  4. 3.1.3 Melanoma Cancer
  5. 3.1.4 Brain Cancer
  6. 3.1.5 Others
  7. 3.2 Global Neoantigen Vaccine Market Size by Application
  8. 3.2.1 Global Neoantigen Vaccine Market Size Overview by Application (2021-2032)
  9. 3.2.2 Global Neoantigen Vaccine Historic Market Size Review by Application (2021-2026)
  10. 3.2.3 Global Neoantigen Vaccine Market Size Forecasted by Application (2027-2032)
  11. 3.3 Global Neoantigen Vaccine Market Size by Regions
  12. 3.3.1 North America Neoantigen Vaccine Market Size Breakdown by Application (2021-2026)
  13. 3.3.2 Europe Neoantigen Vaccine Market Size Breakdown by Application (2021-2026)
  14. 3.3.3 Asia-Pacific Neoantigen Vaccine Market Size Breakdown by Application (2021-2026)
  15. 3.3.4 South America Neoantigen Vaccine Market Size Breakdown by Application (2021-2026)
  16. 3.3.5 Middle East and Africa Neoantigen Vaccine Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Neoantigen Vaccine Industry Trends
  2. 4.2 Neoantigen Vaccine Industry Drivers
  3. 4.3 Neoantigen Vaccine Industry Opportunities and Challenges
  4. 4.4 Neoantigen Vaccine Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Neoantigen Vaccine Revenue (2021-2026)
  2. 5.2 Global Neoantigen Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Neoantigen Vaccine Key Company Headquarters & Area Served
  4. 5.4 Global Neoantigen Vaccine Company, Product Type & Application
  5. 5.5 Global Neoantigen Vaccine Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Neoantigen Vaccine Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Neoantigen Vaccine Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Neoantigen Vaccine Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Merck & Co Inc
  2. 6.1.1 Merck & Co Inc Company Information
  3. 6.1.2 Merck & Co Inc Business Overview
  4. 6.1.3 Merck & Co Inc Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Merck & Co Inc Neoantigen Vaccine Product Portfolio
  6. 6.1.5 Merck & Co Inc Recent Developments
  7. 6.2 Eli Lilly and Company
  8. 6.2.1 Eli Lilly and Company Company Information
  9. 6.2.2 Eli Lilly and Company Business Overview
  10. 6.2.3 Eli Lilly and Company Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Eli Lilly and Company Neoantigen Vaccine Product Portfolio
  12. 6.2.5 Eli Lilly and Company Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Pfizer Neoantigen Vaccine Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 ZIOPHARM Oncology
  20. 6.4.1 ZIOPHARM Oncology Company Information
  21. 6.4.2 ZIOPHARM Oncology Business Overview
  22. 6.4.3 ZIOPHARM Oncology Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 ZIOPHARM Oncology Neoantigen Vaccine Product Portfolio
  24. 6.4.5 ZIOPHARM Oncology Recent Developments
  25. 6.5 Vaximm AG
  26. 6.5.1 Vaximm AG Company Information
  27. 6.5.2 Vaximm AG Business Overview
  28. 6.5.3 Vaximm AG Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Vaximm AG Neoantigen Vaccine Product Portfolio
  30. 6.5.5 Vaximm AG Recent Developments
  31. 6.6 Vaccibody AS
  32. 6.6.1 Vaccibody AS Company Information
  33. 6.6.2 Vaccibody AS Business Overview
  34. 6.6.3 Vaccibody AS Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Vaccibody AS Neoantigen Vaccine Product Portfolio
  36. 6.6.5 Vaccibody AS Recent Developments
  37. 6.7 Roche Holding AG
  38. 6.7.1 Roche Holding AG Company Information
  39. 6.7.2 Roche Holding AG Business Overview
  40. 6.7.3 Roche Holding AG Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Roche Holding AG Neoantigen Vaccine Product Portfolio
  42. 6.7.5 Roche Holding AG Recent Developments
  43. 6.8 OSE Immunotherapeutics
  44. 6.8.1 OSE Immunotherapeutics Company Information
  45. 6.8.2 OSE Immunotherapeutics Business Overview
  46. 6.8.3 OSE Immunotherapeutics Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 OSE Immunotherapeutics Neoantigen Vaccine Product Portfolio
  48. 6.8.5 OSE Immunotherapeutics Recent Developments
  49. 6.9 Novogene
  50. 6.9.1 Novogene Company Information
  51. 6.9.2 Novogene Business Overview
  52. 6.9.3 Novogene Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Novogene Neoantigen Vaccine Product Portfolio
  54. 6.9.5 Novogene Recent Developments
  55. 6.10 Nouscom
  56. 6.10.1 Nouscom Company Information
  57. 6.10.2 Nouscom Business Overview
  58. 6.10.3 Nouscom Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Nouscom Neoantigen Vaccine Product Portfolio
  60. 6.10.5 Nouscom Recent Developments
  61. 6.11 Moderna
  62. 6.11.1 Moderna Company Information
  63. 6.11.2 Moderna Business Overview
  64. 6.11.3 Moderna Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Moderna Neoantigen Vaccine Product Portfolio
  66. 6.11.5 Moderna Recent Developments
  67. 6.12 Medigene AG
  68. 6.12.1 Medigene AG Company Information
  69. 6.12.2 Medigene AG Business Overview
  70. 6.12.3 Medigene AG Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Medigene AG Neoantigen Vaccine Product Portfolio
  72. 6.12.5 Medigene AG Recent Developments
  73. 6.13 ISA Pharmaceuticals
  74. 6.13.1 ISA Pharmaceuticals Company Information
  75. 6.13.2 ISA Pharmaceuticals Business Overview
  76. 6.13.3 ISA Pharmaceuticals Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 ISA Pharmaceuticals Neoantigen Vaccine Product Portfolio
  78. 6.13.5 ISA Pharmaceuticals Recent Developments
  79. 6.14 Gritstone Bio
  80. 6.14.1 Gritstone Bio Company Information
  81. 6.14.2 Gritstone Bio Business Overview
  82. 6.14.3 Gritstone Bio Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Gritstone Bio Neoantigen Vaccine Product Portfolio
  84. 6.14.5 Gritstone Bio Recent Developments
  85. 6.15 Genocea Biosciences Inc
  86. 6.15.1 Genocea Biosciences Inc Company Information
  87. 6.15.2 Genocea Biosciences Inc Business Overview
  88. 6.15.3 Genocea Biosciences Inc Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Genocea Biosciences Inc Neoantigen Vaccine Product Portfolio
  90. 6.15.5 Genocea Biosciences Inc Recent Developments
  91. 6.16 BrightPath Biotherapeutics
  92. 6.16.1 BrightPath Biotherapeutics Company Information
  93. 6.16.2 BrightPath Biotherapeutics Business Overview
  94. 6.16.3 BrightPath Biotherapeutics Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 BrightPath Biotherapeutics Neoantigen Vaccine Product Portfolio
  96. 6.16.5 BrightPath Biotherapeutics Recent Developments
  97. 6.17 BioNTech
  98. 6.17.1 BioNTech Company Information
  99. 6.17.2 BioNTech Business Overview
  100. 6.17.3 BioNTech Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 BioNTech Neoantigen Vaccine Product Portfolio
  102. 6.17.5 BioNTech Recent Developments
  103. 6.18 Avidea Technologies
  104. 6.18.1 Avidea Technologies Company Information
  105. 6.18.2 Avidea Technologies Business Overview
  106. 6.18.3 Avidea Technologies Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Avidea Technologies Neoantigen Vaccine Product Portfolio
  108. 6.18.5 Avidea Technologies Recent Developments
  109. 6.19 Agenus Inc
  110. 6.19.1 Agenus Inc Company Information
  111. 6.19.2 Agenus Inc Business Overview
  112. 6.19.3 Agenus Inc Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Agenus Inc Neoantigen Vaccine Product Portfolio
  114. 6.19.5 Agenus Inc Recent Developments
  115. 6.20 Advaxis
  116. 6.20.1 Advaxis Company Information
  117. 6.20.2 Advaxis Business Overview
  118. 6.20.3 Advaxis Neoantigen Vaccine Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 Advaxis Neoantigen Vaccine Product Portfolio
  120. 6.20.5 Advaxis Recent Developments
7 North America
  1. 7.1 North America Neoantigen Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Neoantigen Vaccine Market Size by Country (2021-2026)
  3. 7.3 North America Neoantigen Vaccine Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Neoantigen Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Neoantigen Vaccine Market Size by Country (2021-2026)
  3. 8.3 Europe Neoantigen Vaccine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Neoantigen Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Neoantigen Vaccine Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Neoantigen Vaccine Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Neoantigen Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Neoantigen Vaccine Market Size by Country (2021-2026)
  3. 10.3 South America Neoantigen Vaccine Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Neoantigen Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Neoantigen Vaccine Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Neoantigen Vaccine Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst